跳至主要内容
临床试验/NCT00161655
NCT00161655已完成4 期

A Multicenter, Open-label, Randomized, Pilot-study to Evaluate the Efficacy and Safety of the Combination of Etanercept (ETN) and Methotrexate and of Etanercept (ETN) Alone in Patients With Plaque Psoriasis Despite Methotrexate Therapy

Wyeth is now a wholly owned subsidiary of Pfizer8 个研究点 分布在 4 个国家目标入组 60 人开始时间: 2005年4月1日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
60
试验地点
8
主要终点
Proportion of pts whose plaque psoriasis is cleared or almost cleared after 24 weeks.

研究概览

简要总结

The purpose of this study is to evaluate the efficacy to clear or almost clear the plaques in plaque psoriasis patients, treated with the combination etanercept and methotrexate compared to etanercept alone.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Active plaque psoriasis involving >10% body surface area and/or minimal screening PASI score
  • Methotrexate >7.5 mg/week for the last 3 months

排除标准

  • Predominantly guttate, erythrodermic or pustular psoriasis
  • Other skin conditions than psoriasis

结局指标

主要结局

Proportion of pts whose plaque psoriasis is cleared or almost cleared after 24 weeks.

次要结局

  • Percentage improvement in PASI. Proportion of pts demonstrating PASI 50, 75
  • and 90. Time to clear or almost clear on PGA.

研究者

发起方
Wyeth is now a wholly owned subsidiary of Pfizer
申办方类型
Industry

研究点 (8)

Loading locations...

相似试验

Study Evaluating Etanercept and Methotrexate in... | 临床试验